Hong Kong-listed Insilico Medicine has forged a partnership with the UAE drug regulator to enhance the application of its AI technologies in drug discovery amid rising geopolitical tensions in the Middle East. This agreement, finalized during the World Health Expo in Dubai, has spurred investor interest, with Insilico’s shares soaring up to 12.8% before closing 8.6% higher at HK$56.10. Concurrently, the Hang Seng Index experienced a modest increase of 0.3%. Despite regional unrest, including military strikes on Iran, which have impacted markets, the collaboration aims to leverage advanced AI platforms utilizing generative models and reinforcement learning algorithms for in-depth analysis of biological and clinical data. Shaikha Al Mazrouei emphasized that this initiative will significantly enhance pharmaceutical research capabilities in the region, positioning Insilico as a leader in implementing innovative AI solutions in drug discovery.
Source link
Share
Read more